Streetbeat News

Earnings

UBX

UNITY Biotechnology reported a Q3 EPS of $(1.05), which is an improvement from the $(1.36) reported in the same quarter of the previous year.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 10:18 pm

EYEN

Eyenovia (NASDAQ:EYEN) reported Q3 EPS of $(0.18), which was in line with analyst estimates, and a significant sales beat of $1.20M against a $150.00K estimate, representing a 698.67% increase.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 10:18 pm

ESP

Espey Mfg & Electronics (AMEX:ESP) reported a 41.94% increase in Q1 EPS to $0.44, up from $0.31 YoY, while sales slightly decreased by 0.78% to $8.57M from $8.64M YoY.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 10:17 pm

PRSO

Peraso (NASDAQ:PRSO) reported Q3 adjusted EPS of $(0.04), surpassing the $(0.10) estimate, and sales of $4.48M, exceeding the $3.05M estimate. This reflects a 60% improvement in EPS and a 36.04% increase in sales compared to the same period last year.

Portfolio Pulse from mahesh@benzinga.com

November 13, 2023 | 10:17 pm

DSGN

Design Therapeutics (NASDAQ:DSGN) reported a Q3 EPS loss of $(0.28), surpassing the consensus estimate of $(0.41) by 31.71%. The reported loss shows a 12.5% improvement from the $(0.32) per share loss in the same quarter last year.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 10:16 pm

MIGI

Mawson Infrastructure Group Inc. reported a 7% increase in revenue for Q3 2023, reaching $11.3 million compared to the previous quarter.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 10:16 pm

ALXO

ALX Oncology Holdings (NASDAQ:ALXO) reported a Q3 EPS loss of $(1.24), missing the consensus estimate of $(0.87) by 42.53%. This represents a 74.65% increase in losses compared to $(0.71) per share in the same quarter last year.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 10:15 pm

ATEX

Anterix reported Q2 adjusted EPS of $(0.27), surpassing the $(0.62) estimate, marking a 51.79% improvement from last year. However, sales of $1.05M fell short of the $1.08M estimate, despite a 164.32% increase from the previous year.

Portfolio Pulse from bharat@benzinga.com

November 13, 2023 | 10:15 pm

PRSO

Peraso Technologies Inc. (PRSO) reported Q3 earnings per share (EPS) of $(0.04), surpassing the $(0.10) estimate, and sales of $4.48M, exceeding the $3.05M estimate. These figures represent a 60% improvement in EPS and a 46.92% beat in sales compared to analyst expectations, as well as a 36.04% increase in sales year-over-year.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 10:15 pm

CYCC

Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported a Q3 EPS loss of $(0.49), missing the consensus estimate of $(0.36) by 36.11%. This represents a 16.67% increase in losses compared to the same period last year.

Portfolio Pulse from mahesh@benzinga.com

November 13, 2023 | 10:14 pm